

1 **Integrated placental modelling of histology with gene expression to identify functional**
2 **impact on fetal growth**

3 Hannah Ee Juen Yong^{1,2*}, Kasia Maksym^{3,4*}, Muhammad Ashraf Bin Yusoff³, Esteban

4 Salazar-Petres¹, Tatiana Nazarenko^{3,5}, Alexey Zaikin^{3,5}, Anna L David^{3,4,6}, Sara L

5 Hillman^{3,4+}, Amanda Nancy Sferruzzi-Perri¹⁺

6

7 *contributed equally; joint first author

8 +contributed equally; joint last and corresponding author

9

10 ¹Centre for Trophoblast Research,

11 Department of Physiology, Development and Neuroscience

12 University of Cambridge

13 Cambridge UK

14 CB2 3EG

15

16 ²Singapore Institute for Clinical Sciences,

17 Agency for Science, Technology and Research,

18 Singapore

19 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

20 ³ Elizabeth Gareth Anderson Institute for Women's Health,

21 University College London,

22 84-86 Chenies Mews, London UK

23 WC1E 6HU

24

25 ⁴ Fetal Medicine Unit

26 Elizabeth Gareth Anderson Wing,

27 University College Hospitals NHS Trust,

28 25 Grafton Way, London UK

29 WC1E 6DB

30

31 ⁵ Department of Mathematics,

32 University College London,

33 London UK

34 WC1E 6AE

35

36 ⁶ National Institute for Health Research University College London Hospitals Biomedical

37 Research Centre, 149 Tottenham Court Road, London W1T 7DN

38

39 Correspondence:

40 Amanda Sferruzzi-Perri

41 ¹Centre for Trophoblast Research,

42 Department of Physiology, Development and Neuroscience

43 University of Cambridge

44 Cambridge UK

45 CB2 3EG

46 +44 (0) 1223 333 807

47 ans48@cam.ac.uk

48

49 Sara Hillman

50 Elizabeth Gareth Anderson Institute for Women's Health,

51 University College London,

52 84-86 Chenies Mews, London UK

53 WC1E 6HU

54 + 44 (0)203 447 6162

55 sara.hillman@ucl.ac.uk

56

57 Conflicts of interest

58 The authors have declared that no conflict of interest exists

59 **Abstract:**

60 Fetal growth restriction (FGR) is a leading cause of perinatal morbidity and mortality. Altered
61 placental formation and functional capacity are major contributors to FGR pathogenesis.
62 Relating placental structure to function across the placenta in healthy and FGR pregnancies
63 remains largely unexplored but could improve understanding of placental diseases. We
64 investigated integration of these parameters spatially in the term human placenta using
65 predictive modelling. Systematic sampling was able to overcome heterogeneity in placental
66 morphological and molecular features. Defects in villous development, elevated fibrosis, and
67 reduced expression of growth and functional marker genes (insulin-like growth factor-2,
68 vascular endothelial growth factor-A, solute carrier family 38 member 1, solute carrier family
69 2 member 3) were seen in age-matched term FGR versus healthy control placentas.
70 Characteristic histopathological changes with specific accompanying molecular signatures
71 could be integrated through computational modelling to predict if the placenta came from a
72 healthy or FGR pregnancy. Our findings yield new insights into the spatial relationship
73 between placental structure and function and the aetiology of FGR.

74

75 Key words: Placenta, FGR, modelling, morphology, growth genes, transport

76

77

78 **Introduction:**

79 The human placenta is a highly specialized organ in pregnancy, whereby normal functioning
80 is critical to fetal development and long term health. By acting as a functional interface between
81 the maternal and fetal circulation, it is responsible for maternal-fetal substrate exchange,
82 protects the fetus from immune rejection by the mother and secretes hormones, which maintain
83 pregnancy and promote healthy fetal growth and development (1, 2). This complex organ is
84 structurally heterogeneous, not only in terms of its broad spatial macroscopic characteristics
85 with multiple cotyledons and vascular supply, but also at the microscopic level of the villous
86 tree and trophoblast. Even in pregnancies that deliver at term without any apparent pathology,
87 novel techniques such as micro-CT are now describing the large degree of heterogeneity of
88 vascular density and branching in the placenta (3). In addition, computational models have
89 predicted that local heterogeneity in placental vascular structure can have major impacts on the
90 resistance of the fetoplacental circulation and placental dysfunction (4). Investigating the
91 spatial relationships between changes in gene expression and structural differences in the
92 placenta is important, so that we may better elucidate the potential functional effect of placental
93 pathology in obstetric disease.

94

95 Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality. The risk
96 of *in utero* or neonatal death is especially high amongst growth restricted fetuses and neonates
97 who are commonly born preterm ([https://www.who.int/publications/i/item/every-newborn-an-](https://www.who.int/publications/i/item/every-newborn-an-action-plan-to-end-preventable-deaths)
98 [action-plan-to-end-preventable-deaths](https://www.who.int/publications/i/item/every-newborn-an-action-plan-to-end-preventable-deaths)). In some regions of the world, FGR and prematurity
99 accounts for 80% of neonatal deaths (5). FGR is diagnosed when a fetus fails to reach their
100 genetically predefined growth potential and is often identified by fetoplacental ultrasound
101 features (such as increased umbilical artery resistance to blood flow), and subsequently

102 confirmed through placental histopathology (6). The gestational age at diagnosis is used to
103 further subdivide FGR into early-onset, detected before 32 weeks of gestation, and late-onset
104 according to international consensus (7). Neonates born following FGR have an increased risk
105 of developing health problems, both in the immediate postnatal period including low blood
106 sugars and poor temperature regulation and feeding, but also in later adult life in the form of
107 cardiovascular and metabolic disease (8, 9). Management of pregnancies affected by FGR can
108 be challenging, as timing of delivery needs to be judged well, to balance the hazards of preterm
109 birth against the risks of irreversible damage secondary to intrauterine hypoxia and nutritional
110 deficiency or even stillbirth (10).

111

112 The placenta of FGR pregnancies is characterized by reduced syncytiotrophoblast surface area,
113 increased thickness of the exchange barrier formed by the trophoblast and fetal capillary
114 endothelium and an increase in placental apoptosis (11-14). This complex series of adaptations
115 in response to dysfunctional placentation affects the ability of the placenta to provide sufficient
116 oxygen and nutrients to the fetus, which in turn, is thought to compromise fetal growth and
117 development. Whilst it is recognized that there are key mediators of fetal growth that are
118 influenced by placental function including but not limited to transfer of gases (15), glucose (16,
119 17), lipids (18) and amino acids (17, 19), direct cause and effect is not clear. Nuanced,
120 integrated investigations are required to better delineate the underlying functional mechanisms
121 related to the histological changes observed in the placenta. Experimental animal data has
122 highlighted central roles that certain structural and functional changes play in the placenta to
123 fetal growth outcomes (20-24). However, data on how structure *and* molecular changes
124 together impact on function and on each other, even in the form of nutrient transporter
125 expression, are scarce or not available for the human placenta (25, 26).

126

127 Better understanding of how placental structure relates to functional capacity is also furthered
128 through optimized and robust placental sampling protocols. Methodological errors arise from
129 differences in sampling and/or tissue processing, which has previously hampered the
130 reproducibility and possible extrapolation of placental studies (27, 28). Systematic uniform
131 random sampling involves random selection of the first sampling site, with subsequent sites
132 dictated by a pre-made sampling interval. This method is recommended to ensure
133 representative and unbiased sampling of the placenta (28, 29). It is a simple method, allowing
134 for even coverage of the placenta and ensures that all sites can only be selected once (28). In
135 practice, however, systematic uniform random sampling has limitations. Firstly, its lack of bias
136 may be compromised if the pre-determined sampling interval coincides with a natural pattern
137 existent in the placenta (29). Secondly, placentae templates designed for systematic uniform
138 random sampling assume all placentas to be roughly circular in shape, with central umbilical
139 cord insertion. This assumption of a uniform shape and cord insertion however is incorrect.
140 Although studies do show that mean placental chorionic shape at term is round, deviations in
141 placental shape are associated with reduced placental efficiency (30). In addition, the point of
142 umbilical cord insertion appears to affect placental function, with a marginal cord insertion
143 near the outer boundary of the placenta resulting in a more asymmetric chorionic vessel
144 structure (31), which has been associated with FGR, stillbirth and neonatal death (32).

145

146 While analysis of single sites may miss important histopathological and functional changes,
147 multiple site collection poses analytical challenges, and methods may still fail to identify
148 critical differences within placentas affected by pathology, such as FGR. Statistical modelling
149 allows for the exploration and integration of multiple data points from the same sample to
150 provide more accurate interpretation of functional consequences. Moreover, the use of
151 modelling to predict regional and disease state differences has high translational potential, for

152 example providing an explanation for why the pregnancy was compromised and which baby
153 may benefit the most from early health monitoring and/or intervention. With this study we
154 therefore, firstly sought to better understand if systematic uniform random sampling methods
155 could be optimised to the challenges FGR placentas pose. Secondly, we sought to characterise
156 the degree of detailed histological and molecular heterogeneity between multiple placental
157 samples in healthy and FGR placentas. Finally, we examined potential links between
158 histological changes and the expression of genes involved in placental formation, transport,
159 and transcriptional regulation, and their relationships with fetal growth/pregnancy outcome by
160 incorporating novel modelling analysis to better delineate the significance of the placenta in
161 health and disease.

162

163 **Results:**

164 **Patient characteristics**

165 We matched FGR cases and controls for maternal age, booking BMI, mode of delivery and
166 infant sex (Table 1) with expanded clinical data available (Supplementary Table 1).
167 Nonetheless, several significant differences in clinical characteristics were still observed. FGR
168 cases were more likely to be non-White and delivered infants with lower birth and placental
169 weights about a week earlier, although all delivered at term ($>36^{+6}$ weeks of gestation).

170

171 **Stereological analysis of placental morphology**

172 Comparing stereological findings by sampling site within the FGR or control groups showed
173 no significant differences between samples taken from the central and peripheral regions of the
174 placenta (Supplementary Table 2). Hence, we averaged the data of the central and peripheral
175 regions of each placenta to compare by pathology (Table 2). Taking into consideration a false
176 discovery rate of 5% for multiple testing, FGR placentas had significantly lower volume

177 densities of intermediate villi, syncytial knots and higher volume densities fibrosis and
178 capillaries. Once placental weight was accounted for, FGR cases showed decreased volumes
179 of intervillous spaces, intermediate villi, terminal villi, syncytial knots, trophoblast and stromal
180 components, and increased volume of fibrosis compared to control placentas. There were no
181 differences in any measure of barrier thickness, surface area, surface densities and diffusion
182 capacities between FGR and control placentas; except that FGR placentas had a decreased villi
183 surface area.

184

185 **Placental expression of growth factors and nutrient transporters**

186 We also evaluated relative mRNA expression of selected growth factors and nutrient
187 transporters (Figure 1) that have been previously implicated in transcriptional control or with
188 compromised fetal growth in humans and animal models of FGR (33-38). Placental *IGF2*,
189 *SLC2A3* and *SLC38A1* expression was significantly lower for FGR versus controls, regardless
190 of sampling location (Figures 1A, 2D and 2E). *VEGFA* expression was significantly lower in
191 the peripheral region as compared to the central region of FGR placentas, while no statistical
192 difference was identified in the central region between cases and controls (Figure 1B). Only
193 *SLC2A1* expression was significantly increased in FGR placenta as compared to controls,
194 independent of sampling location (Figure 1C). No differences in mRNA expression of and
195 *SLC38A2* were observed between FGR and control placentas or by sampling location (Figure
196 1F). In controls, placental *HNF1A* expression was higher in the peripheral region as compared
197 to the central region (Figure 1G), but no differences were identified for FGR.

198

199 **Associations between placental morphology and expression of functional genes**

200 We next evaluated relationships between placental morphology and the expression of growth
201 factor and nutrient transporter genes within the different sampling sites, and between control

202 and FGR groups using Pearson's r coefficient (Figure 2). In FGR placentas, several inverse
203 correlations were identified between expression of *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* and
204 the volume of terminal villi, trophoblast, and capillary volume predominantly in the peripheral
205 region of FGR placentas. Inverse correlations with fibrosis volume were also observed for
206 expression *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* in the central region of FGR placentas.
207 Additionally, the relative expression of *IGF2*, *VEGFA*, *SLC38A1* and *SLC2A3* genes was
208 inversely correlated with barrier thickness uniformity index and both maternal blood spaces
209 and fetal capillaries surface densities in the FGR placenta (central and peripheral sites),
210 although no significant correlations were detected for the control placenta. Moreover, the
211 expression of *IGF2*, *SLC38A1* and *SLC2A3* genes negatively correlated with both theoretical
212 and specific diffusion capacity in FGR, but not control placentas. In contrast, FGR expression
213 of *HNF1A* showed a positive correlation with specific diffusion capacity in the peripheral
214 region. Positive correlations between the expression of all genes measured and fibrosis and
215 stromal volumes were found for the peripheral region of control placentas, but not FGR
216 placentas. Positive relationships were also seen for expression of *VEGFA* and *HNF1A* with
217 the stem villi volume in central sites of control placentas.

218

219 **Predictive modelling**

220 To evaluate the information gained from different placental regions/sampling sites (only
221 peripheral, only central, or both together) and data types (only stereological data, only qPCR
222 data or both together), we considered all their possible combinations using predictive
223 modelling (construction of classifiers that would make it possible to distinguish patients in the
224 control group from patients with FGR). As predictive modelling was carried out using three
225 machine learning (ML) methods; *xgbTree*, *glmnet* and *nnet*, this resulted in 27 models for
226 consideration. The binary outcome of FGR was used as an outcome with chosen set of features

227 (only stereological data, only qPCR data, both data types together) used as predictors. The
228 predictive performance of each model was assessed using a leave-one-out cross-validation
229 (LOOCV) scheme: the prediction was made for each patient (with all measurements) by
230 excluding (withholding) it from the dataset, training the classifier on the remaining
231 (independent) samples, and then generating predictions for the withheld samples using the
232 trained model. Using predictions on the training subset (on each round of LOOCV procedures),
233 the best threshold (corresponding to the best sum of sensitivity plus specificity) distinguishing
234 controls from FGR cases was found and a binary result was calculated for each withheld sample
235 (1 indicated FGR if the prediction was above the threshold, and 0 indicated control if it was
236 below the threshold). Through all rounds, LOOCV procedure binary results were collected for
237 withheld samples and performance was assessed using by these sets of predictions.
238 Performance was estimated using areas under the ROC curve (AUCs) in 2 ways: “AUC for all
239 samples” and “AUC for all patients”, as described in Methods. For each combination of
240 “placenta part + type of measurement + ML model” two such AUC values were obtained. Full
241 results of these analyses can be found in Table 3 (in addition, we provide a complete table of
242 errors for each patient in Supplementary Table 3). For a simplified visualization of these
243 results, we considered the distributions of results (AUCs) of different types of ML models on
244 different types of data obtained in different parts of the placenta for all patients and for all their
245 samples separately (Figure 3). This plot clearly shows that among the considered models, the
246 best are those based on measurements performed on the peripheral parts of the placenta and
247 using stereological and qPCR data together. As shown in Table 3, the best model was found to
248 be *nnet*, i.e., the model using simple artificial neural networks for a classification. This model
249 gave the best result for both “AUC for all samples” (0.979) and “AUC for all patients” (0.917).
250 By considering the stereological and qPCR data separately, the stereological data showed a
251 greater predictive power than the qPCR data (Figure 3, for all variants), which, may be due to

252 the clearly different interdependences of the stereological parameters of the control group and
253 the FGR group (the most significant interdependences are presented in Supplementary Figure
254 1). However, a combination of stereology and qPCR data works better than just stereology for
255 analyses on peripheral parts of the placenta (Figure 3). The results obtained on the central parts
256 of the placenta were lower than the results obtained on both parts of the placenta or only on the
257 peripheral (boxplots for the central parts are slightly lower than the other options). Moreover,
258 results using only peripheral parts were better than using a combination of both parts. Thus,
259 the best model would be that based on measures made on the peripheral parts of the placenta
260 using stereological and qPCR data together.

261

262 **Discussion**

263 There was no significant variability in the morphological features of the placenta within and
264 between the peripheral and central sites of the placenta, regardless of whether they came from
265 a healthy or FGR pregnancy. In addition, the findings indicate that alterations in placental
266 morphology may be uniform across the placenta in late-onset FGR pregnancies without other
267 complications, such as pre-eclampsia, that can lead to more variable histological changes
268 across the placenta (39).

269

270 Despite established evidence that the placenta drives a number of the ‘great obstetrical’
271 syndromes, which includes FGR, the relatively poor understanding of underlying placental
272 mechanisms makes interpretation of how they contribute to clinical presentations difficult (40).
273 Heterogeneity within the placenta is thought to be responsible for some of the difficulties in
274 directly relating disease state to placental findings. Our results suggest that the systematic
275 sampling technique that we used, was able to overcome potential morphological spatial
276 heterogeneity of the term placenta. Indeed, peripheral versus central region comparisons

277 revealed unique features in gene expression correlations and predictive modelling results.
278 These findings enable more clinical interpretations to be made of the results and that use of the
279 same sampling technique may allow for improved reproducibility between placental studies.

280

281 Morphological differences between the control and FGR placenta are consistent with findings
282 of others (41), and indicate villous maldevelopment, with fewer mature intermediate and
283 terminal villi and reduced villous surface area, as well as elevated fibrosis. The increased
284 villous capillary density and reduced syncytial knots in the studied FGR placentas are novel
285 findings and may reflect adaptive responses to hypoxic-reoxygenation events secondary to
286 reduced utero-placental and/or feto-placental flows in FGR pregnancies (42-44).

287 Morphological findings provide a clue to underlying placental mechanisms that may be subject
288 to change, with the resultant amelioration of disease and improvement to fetal outcome, if they
289 can be enacted *in utero*. There is already significant interest in delivery of targeted agents to
290 the uterine arteries to improve blood flow (45). Delivery of agents to target specific areas of
291 pathology and functional deficit within the placenta to improve the clinical condition may also
292 be a potential therapeutic option.

293

294 Our approach to combine morphological assessments with gene expression aimed to identify
295 some key aetiological pathways for the pathology seen. Expression of placental *IGF2*, *SLC2A3*
296 and *SLC38A1* was lower across the FGR placenta, correlating with volumes and other specific
297 placental features, suggesting a global role for these molecules in placental structure and
298 development in the presence of FGR. Indeed, *IGF2* is known to be important for the formation
299 of the placental exchange interface in humans, among other species (37, 38, 46), and is
300 expressed at lower levels in placentas showing FGR/small for gestational age in some (47, 48),
301 but not all studies (49). Prior work has shown that a genetic deficiency of *SLC2A3* in mice

302 leads to FGR in mice (36), which supports our findings, but is in contrast to other work
303 reporting an upregulation of its encoded protein in the human placenta of late-onset FGR (50).
304 Of the system A amino acid transporters expressed by the human placenta, *SLC38A1* is key for
305 system A activity at term (51). Other work has also shown that placental system A activity is
306 reduced in explants prepared from term FGR placentas (52). *VEGFA* was significantly lower
307 in the peripheral region of the placenta in FGR and correlated to the following placental
308 pathology (terminal villi, trophoblast and capillary volume) that might suggest a causal
309 association. This is consistent with other work reporting lower placental *VEGFA* expression at
310 term in late onset FGR (53, 54), and the involvement of angiogenic factors more generally in
311 normal and pathological pregnancies (55). Our findings also have relevance for emerging pre-
312 clinical research in placenta-directed gene therapy for FGR, including the utility of insulin-like
313 growth factors and angiogenic regulators (56). *HNF1A* was more highly expressed by the
314 peripheral region compared with central region in healthy, but not FGR placentas. Little is
315 known about the function of *HNF1A* in the placenta, although the human tissue atlas indicates
316 it is abundantly expressed by the villous syncytiotrophoblast
317 (<https://www.proteinatlas.org/ENSG00000135100-HNF1A/tissue/placenta>). Recent work has
318 highlighted that *HNF1A* may regulate a large number of genes in trophoblast cells (57) and
319 mediate metabolic changes (58), which could be important for the placental support of fetal
320 growth, more broadly.

321

322 Using predictive modelling, we demonstrated the potential of predicting outcome (control or
323 FGR) based on stereology and qPCR data, hence, proving a link between the data analysed and
324 functional roles in the placenta. Stereology and qPCR measurements taken from the peripheral
325 part of the placenta, and analysed together, have the highest predictive power. To avoid any
326 possible overfitting of the models, we did not perform any feature selection in advance for

327 tuning of the algorithm hyperparameters. Despite this, we were able to obtain predictions with
328 very high accuracy, as, in fact, for the best model only one sample out of 60 (4 samples from
329 peripheral placenta part for each of 15 patients) considered was predicted incorrectly. This one
330 sample belonged to a subject (Patient FGR 6) who needed a caesarean section due to an
331 immediate life-threatening situation (Cat1 CS) and was noted to be obese (BMI >35kg/m²;
332 obese category 2). Indeed, this subject was one that was most likely to be misclassified in all
333 the tested models. Nevertheless, we found that the morphological data clearly shows separation
334 of features for control and FGR placentas and probably, this made it possible to obtain high
335 quality constructed models. For the present study, we used a very strict LOOCV. It did not
336 provide us with one final model but brings the hope that testing our predictive model in a larger
337 dataset, with extremes of pathology, may help improve accuracy and sensitivity of the model
338 developed. Whilst modelling predictions were poor for qPCR data used alone, it is important
339 to mention that adding these data to the analysis of stereology data improved prediction, hence,
340 confirming importance of qPCR data and underlying link of these data with functional features.

341

342 Overall, our data add to current understanding of placental function through comprehensive
343 sampling of healthy placentas and those affected by disease (FGR) with careful deep
344 histological analysis, integrated with expression of genes with key biological pathways
345 implicated in poor placental function. Whilst, our modelling approach still requires some
346 validation, with further pathology analysed, it offers the promise of better diagnostic yield and
347 novel insight into biological pathways that affect FGR pregnancies.

348

349 **Material and methods:**

350 *Placental tissue collection and sampling*

351 Subjects were recruited from University College London Hospital NHS Foundation Trust,
352 London, UK with ethics approval from the South-Central Oxford A research ethics committee
353 (17/SC/0432). After written informed consent was obtained, term placental biopsies were
354 collected from subjects diagnosed with late-onset FGR (n=7, FGR detected after 32 weeks'
355 gestation and an estimated fetal weight and/or abdominal circumference below 3rd centile on
356 population-based charts used clinically (59)), and from control subjects with appropriately
357 grown fetuses (n=9 birthweight >10th centile and <90th centile). Data on maternal pre-existing
358 conditions, previous obstetric history, ultrasound examination, and pregnancy complications
359 were collected at the time of recruitment.

360

361 Placentas were weighed and sampled within 30 minutes of delivery. Sampling sites were
362 chosen to be representative of four central and four peripheral regions always relative to cord
363 insertion (Figure 4A). In marginal cord insertions, the placenta was orientated with the cord
364 anterior. Sampling then took place relative to the cord insertion as in other cases. This meant
365 there was one site that had less tissue to sample from initially, in non-central cord insertions,
366 but that ultimately the same amount of tissue was sampled, and that tissue selection was directly
367 related to the cord in the same way as all other samples. For each placenta, 8 tissue biopsies
368 (with maternal tissue and fetal chorionic plate removed) were snap frozen using liquid nitrogen
369 or dry ice and stored at -80°C. Neighboring sampling sites were then immersion-fixed in 4%
370 paraformaldehyde.

371

372 ***RNA extraction, cDNA synthesis and qPCR***

373 Total RNA was extracted from n=9 control and n=6 FGR frozen placental tissues (n=1 FGR
374 sample was not taken due to delay in freezing this sample) using the RNeasy Fibrous Tissue
375 Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Briefly,
376 approximately 2mg of tissue was added to 300µl of lysis buffer and homogenized using a bead-
377 based technique. Following treatment with proteinase K and addition of 100% ethanol, the
378 homogenate was transferred to the spin columns, washed with supplied buffers and centrifuged
379 to remove contaminants. Purified RNA was then eluted into RNase-free water. Quality and
380 concentration of extracted RNA were determined by Nanodrop (Thermo Fisher Scientific,
381 Waltham, CA, USA).

382

383 Complementary DNA (cDNA) was synthesized using the Applied Biosystems High-Capacity
384 cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to manufacturer's
385 instructions on a thermal cycler. Real-time PCR was performed in duplicate using TaqMan™
386 Universal Master Mix II, with UNG (Thermo Fisher Scientific) and inventoried TaqMan®
387 gene expression assay probes with either VIC and FAM fluorophores for 5 housekeeping genes
388 (*18SrRNA*, *B2M*, *GAPDH*, *GUSB* and *YWHAZ*) and 8 genes of interest (*HNF1A*, *IGF2*,
389 *SLC2A1*, *SLC2A3*, *SLC38A1*, *SLC38A2*, *SLC38A4* and *VEGFA*) (Table 4). Only stable
390 housekeeping genes (*18S rRNA*, *B2M*, *GADPH* and *YWHAZ*) that showed no statistically
391 significant differences between cases and controls were included in the housekeeper geomean
392 calculation for normalising gene expression across samples. The relative expression of genes
393 of interest was then calculated using the $2^{-\Delta\Delta Ct}$ method.

394

395 ***Histological preparation***

396 Following paraformaldehyde fixation, biopsies of 8 sites from each control (n=9) and FGR
397 (n=7) placenta were embedded in paraffin using routine histological techniques and sectioned
398 at 7µm thickness. Sections were rehydrated using xylene and ethanol gradients, stained with
399 haematoxylin and eosin, dehydrated with ethanol gradients and xylene, then mounted with
400 DPX. Slides were then scanned using a Nanozoomer digital slide scanner (Hamamatsu
401 Photonics, Shizuoka Prefecture, Japan).

402

403 ***Placental stereology***

404 Placentas were analysed blinded to the diagnosis of FGR. To perform stereological analysis in
405 a manner similar to that performed previously (60); transparent lattices with test points, test
406 lines or test arcs were superimposed onto scanned images viewed under different magnification
407 on the NDP.view2 software (Hamamatsu Photonics). Volume densities of the intervillous
408 space, stem villi, intermediate villi, terminal villi, syncytial knots, and fibrosis (Figure 4B-C)
409 were estimated by point counting and a lattice of equally spaced test points arranged 4 by 4
410 under 10X magnification in at least 13 fields of view for a minimum of 200 measurements per
411 section. Volume densities of the trophoblast, stroma, and fetal capillaries (Figure 4D) within
412 villi were estimated under a similar lattice under 40X magnification in 20 fields of view per
413 sample. Absolute placental volumes were estimated by multiplying volume densities with
414 placental weight (g). Arithmetic barrier thickness was assessed under 100X magnification in
415 20 fields of view per sample and a superimposed lattice with equally spaced straight test lines,
416 which at times, intersected fetal capillary and villous trophoblast involved in exchange. The
417 ‘measure’ tool within the software was then used to determine the shortest distance between a
418 fetal capillary and the maternal blood space, where there was an intersection. Mean harmonic
419 barrier thickness was calculated using the inverse of mean reciprocal of each raw arithmetic

420 barrier thickness measurement. Thickness uniformity index, as a measure of the variability in
421 thickness across the villous membrane, was obtained from the ratio of the mean arithmetic
422 barrier thickness to the mean harmonic barrier thickness. Surface densities were approximated
423 by counting chance intersections of fetal capillaries and villous trophoblast involved in
424 exchange with superimposed test arc lines under 40X magnification. To derive surface areas,
425 surface densities were multiplied by placental villous volume. The theoretical diffusion
426 capacity was calculated using the total surface area for exchange (averaged surface area of fetal
427 capillaries and villi) divided by the mean harmonic barrier thickness and multiplied by Krogh's
428 constant for oxygen diffusion. Specific diffusion capacity was then calculated by dividing the
429 theoretical diffusion capacity by the infant birthweight.

430

431 *Predictive modelling*

432 To evaluate the informativity of different placental sampling locations (only peripheral, only
433 central or both regions together) and different data types (only stereological data, only PCR
434 data or both types together), we studied all their possible combinations with analysis
435 performed in R (version 4.0.2). To analyse several well-established multi-dimensional methods
436 of data analysis, the machine learning models (*xgbTree*, *glmnet* and *nnet*) were implemented
437 using *caret* package (version 6.0.90). All 27 models were trained with default set of
438 hyperparameters, cross-validated on 5 folds (for a better selection of internal algorithm
439 parameters), with seed parameter set to 123. The performance of models was assessed with
440 receiver operating characteristic (ROC) curves using area under the curve (AUC) with 95%
441 confidence intervals (*pROC* package, version 1.18.0). Results of AUCs were presented in two
442 ways:

443 - *All sample's AUC* - Calculating AUC considering all samples as independent;

444 - *All patient's AUC* - Calculating AUC on patient's result's only (if all samples belonging
445 to one patient were correctly predicted, then we assumed that a prediction for this
446 patient was correct, if the prediction was wrong in at least one sample of the sample's
447 patient, then it was set as wrong for this patient).

448 For illustration of interdependencies of features, which are presented in Supplementary Figure
449 1, we selected the best pairs that showed significant differences between FGR and control
450 groups using ANOVA test after applying FDR (false discovery rate) adjustment to test's p-
451 values (*stats* package, Version 4.0.2).

452

453 *Statistical analyses*

454 Normality of data was assessed by D'Agostino-Pearson normality test. ROUT testing for
455 outliers was used to identify any outliers, which were then excluded from the analysis. For
456 comparisons between 2 groups, Student's t tests and Mann-Whitney U tests were performed
457 for parametric and non-parametric continuous data, respectively. Categorical data between
458 FGR and controls were analysed by a 2 X 2 contingency table with Fisher's Exact Test. Two-
459 way ANOVAs followed by Sidak post hoc test for multiple comparisons were used to analyse
460 mRNA expression data by pathology and sampling location. Graphpad Prism 6.01 (Graphpad
461 Software Inc., La Jolla, CA, USA) was used for statistical analyses. A p-value of <0.05 was
462 considered statistically significant for clinical characteristics and mRNA expression analysis.
463 To account for multiple testing in histological analyses, a false discovery rate correction at 5%
464 was applied to determine statistical significance.

465

466 *Study approval*

467 Subjects were recruited from University College London Hospital NHS Foundation Trust,
468 London, UK with ethics approval from the South-Central Oxford A research ethics committee

469 (17/SC/0432) and the Stanmore research ethics committee (13/LO/1254). Written informed
470 consent was received prior to participation.

471

472 **Author contributions**

473 HEJY, KM, SLH and ANSP designed the study. HEJY, KM, MABY, ESP collected and/or
474 performed experiments. HEJY, KM, ESP and TN analysed and graphed the data. TN and AZ
475 provided predictive modelling analysis. HEJY, KM, TN, AZ, ALD, SLH and ANSP interpreted
476 the data. HEJY, KM, SLH and ANSP wrote the paper. All authors performed final editing
477 checks and approved the final manuscript.

478

479 **Acknowledgements**

480 ANSP received funding for this work via an Academy of Medical Sciences Springboard Grant,
481 Royal Society Dorothy Hodgkin Research Fellowship (DH130036/RG74249), MRC New
482 Investigator Grant (MR/R022690/1/RG93186) and Lister Institute of Preventative Medicine
483 Research Prize (RG93692). TN and AZ are supported by a Medical Research Council grant
484 (MR/R02524X/1). HEJY was supported by an A*STAR International Fellowship from the
485 Agency for Science, Technology and Research. KM was supported by UCLH Charity. SLH
486 received funding for this work via an Academy of Medical Sciences Clinical Lecturer Starter
487 Grant (AMS-SGL015\ 1011) and the UCLH EGA Obstetric Charity.

488

489 **Data availability**

490 All data produced in the present study are available upon reasonable request to the authors.

491

492 **References**

- 493 1. Napso T, Yong HE, Lopez-Tello J, and Sferruzzi-Perri AN. The role of placental
494 hormones in mediating maternal adaptations to support pregnancy and lactation.
495 *Front Physiology*. 2018;9:1091.
- 496 2. Burton GJ, Fowden AL, and Thornburg KL. Placental Origins of Chronic Disease.
497 *Physiol Rev*. 2016;96(4):1509-65.
- 498 3. Byrne M, Aughwane R, James JL, Hutchinson JC, Arthurs OJ, Sebire NJ, et al.
499 Structure-function relationships in the fetoplacental circulation from in silico
500 interpretation of micro-CT vascular structures. *J Theor Biol*. 2021;517:110630.
- 501 4. Aughwane R, Schaaf C, Hutchinson JC, Virasami A, Zuluaga MA, Sebire N, et al.
502 Micro-CT and histological investigation of the spatial pattern of fetoplacental
503 vascular density. *Placenta*. 2019;88:36-43.
- 504 5. Lawn JE, Blencowe H, Oza S, You D, Lee AC, Waiswa P, et al. Every Newborn:
505 progress, priorities, and potential beyond survival. *Lancet*. 2014;384(9938):189-205.
- 506 6. Sharma D, Shastri S, and Sharma P. Intrauterine Growth Restriction: Antenatal and
507 Postnatal Aspects. *Clinical medicine insights Pediatrics*. 2016;10:67-83.
- 508 7. Gordijn SJ, Beune IM, Thilaganathan B, Papageorgiou A, Baschat AA, Baker PN, et
509 al. Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound*
510 *Obstet Gynecol*. 2016;48(3):333-9.
- 511 8. Van den Berg BJ, and Yerushalmy J. The relationship of the rate of intrauterine
512 growth of infants of low birth weight to mortality, morbidity, and congenital
513 anomalies. *J Pediatr*. 1966;69(4):531-45.
- 514 9. Bianchi ME, and Restrepo JM. Low Birthweight as a Risk Factor for Non-
515 communicable Diseases in Adults. *Front Med (Lausanne)*. 2021;8:793990.

- 516 10. Caradeux J, Martinez-Portilla RJ, Basuki TR, Kiserud T, and Figueras F. Risk of fetal
517 death in growth-restricted fetuses with umbilical and/or ductus venosus absent or
518 reversed end-diastolic velocities before 34 weeks of gestation: a systematic review
519 and meta-analysis. *Am J Obstet Gynecol*. 2018;218(2S):S774-S82 e21.
- 520 11. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, and Maruo T.
521 Increased apoptosis in the syncytiotrophoblast in human term placentas complicated
522 by either preeclampsia or intrauterine growth retardation. *Am J Obstet Gynecol*.
523 2002;186(1):158-66.
- 524 12. Mayhew TM, Wijesekara J, Baker PN, and Ong SS. Morphometric evidence that
525 villous development and fetoplacental angiogenesis are compromised by intrauterine
526 growth restriction but not by pre-eclampsia. *Placenta*. 2004;25(10):829-33.
- 527 13. Macara L, Kingdom JC, Kaufmann P, Kohnen G, Hair J, More IA, et al. Structural
528 analysis of placental terminal villi from growth-restricted pregnancies with abnormal
529 umbilical artery Doppler waveforms. *Placenta*. 1996;17(1):37-48.
- 530 14. Teasdale F, and Jean-Jacques G. Intrauterine growth retardation: morphometry of the
531 microvillous membrane of the human placenta. *Placenta*. 1988;9(1):47-55.
- 532 15. Burton GJ, and Fowden AL. The placenta: a multifaceted, transient organ.
533 *Philosophical transactions of the Royal Society of London Series B, Biological*
534 *sciences*. 2015;370(1663):20140066.
- 535 16. Chavatte-Palmer P, and Tarrade A. Placentation in different mammalian species. *Ann*
536 *Endocrinol (Paris)*. 2016;77(2):67-74.
- 537 17. Pere MC. Materno-foetal exchanges and utilisation of nutrients by the foetus:
538 comparison between species. *Reprod Nutr Dev*. 2003;43(1):1-15.
- 539 18. Crawford MA, Hassam AG, and Williams G. Essential fatty acids and fetal brain
540 growth. *Lancet*. 1976;1(7957):452-3.

- 541 19. Gresham EL, Simons PS, and Battaglia FC. Maternal-fetal urea concentration
542 difference in man: metabolic significance. *J Pediatr.* 1971;79(5):809-11.
- 543 20. Sferruzzi-Perri AN, Vaughan OR, Coan PM, Suci MC, Darbyshire R, Constanica M,
544 et al. Placental-specific Igf2 deficiency alters developmental adaptations to
545 undernutrition in mice. *Endocrinology.* 2011;152(8):3202-12.
- 546 21. Sferruzzi-Perri AN, Vaughan OR, Haro M, Cooper WN, Musial B, Charalambous M,
547 et al. An obesogenic diet during mouse pregnancy modifies maternal nutrient
548 partitioning and the fetal growth trajectory. *FASEB.* 2013;27(10):3928-37.
- 549 22. Vaughan OR, Sferruzzi-Perri AN, and Fowden AL. Maternal corticosterone regulates
550 nutrient allocation to fetal growth in mice. *Journal of Physiology.* 2012;590(21):5529-
551 40.
- 552 23. Higgins JS, Vaughan OR, de Liger EF, Fowden AL, and Sferruzzi-Perri AN.
553 Placental phenotype and resource allocation to fetal growth are modified by the
554 timing and degree of hypoxia during mouse pregnancy. *J Physiol.* 2015;594(5):1341-
555 56.
- 556 24. Napso T, Hung YP, Davidge ST, Care AS, and Sferruzzi-Perri AN. Advanced
557 maternal age compromises fetal growth and induces sex-specific changes in placental
558 phenotype in rats. *Sci Rep.* 2019;9(1):16916.
- 559 25. Lewis RM, and Sferruzzi-Perri AN. In: Poston L, Godfrey KM, Hanson MA, and
560 Gluckman P eds. *Developmental Origins of Health and Disease.* Cambridge
561 University Press.
- 562 26. Audette MC, McLaughlin K, and Kingdom JC. Second Trimester Placental Growth
563 Factor Levels and Placental Histopathology in Low-Risk Nulliparous Pregnancies. *J*
564 *Obstet Gynaecol Can.* 2021;43(10):1145-52 e1.

- 565 27. Burton GJ, Sebire NJ, Myatt L, Tannetta D, Wang YL, Sadovsky Y, et al. Optimising
566 sample collection for placental research. *Placenta*. 2014;35(1):9-22.
- 567 28. Mayhew TM. Taking tissue samples from the placenta: an illustration of principles
568 and strategies. *Placenta*. 2008;29(1):1-14.
- 569 29. Mayhew TM. Morphomics: An integral part of systems biology of the human
570 placenta. *Placenta*. 2015;36(4):329-40.
- 571 30. Salafia CM, Yampolsky M, Misra DP, Shlakter O, Haas D, Eucker B, et al. Placental
572 surface shape, function, and effects of maternal and fetal vascular pathology.
573 *Placenta*. 2010;31(11):958-62.
- 574 31. Gordon Z, Elad D, Almog R, Hazan Y, Jaffa AJ, and Eytan O. Anthropometry of fetal
575 vasculature in the chorionic plate. *J Anat*. 2007;211(6):698-706.
- 576 32. Heifetz SA. The umbilical cord: obstetrically important lesions. *Clin Obstet Gynecol*.
577 1996;39(3):571-87.
- 578 33. Sferruzzi-Perri AN, and Camm EJ. The programming power of the placenta.
579 *Frontiers in Physiology*. 2016;7:33.
- 580 34. Vaughan OR, Maksym K, Silva E, Barentsen K, Anthony RV, Brown TL, et al.
581 Placenta-specific Slc38a2/SNAT2 knockdown causes fetal growth restriction in mice.
582 *Clin Sci (Lond)*. 2021;135(17):2049-66.
- 583 35. Luscher BP, Marini C, Joerger-Messerli MS, Huang X, Hediger MA, Albrecht C, et
584 al. Placental glucose transporter (GLUT)-1 is down-regulated in preeclampsia.
585 *Placenta*. 2017;55:94-9.
- 586 36. Ganguly A, McKnight RA, Raychaudhuri S, Shin BC, Ma Z, Moley K, et al. Glucose
587 transporter isoform-3 mutations cause early pregnancy loss and fetal growth
588 restriction. *Am J Physiol Endocrinol Metab*. 2007;292(5):E1241-55.

- 589 37. Sferruzzi-Perri AN, Owens JA, Pringle KG, and Roberts CT. The neglected role of
590 insulin-like growth factors in the maternal circulation regulating fetal growth. *Journal*
591 *of Physiology* 2010;589(Pt 1):7-20.
- 592 38. Sferruzzi-Perri AN, Sandovici I, Constancia M, and Fowden AL. Placental phenotype
593 and the insulin-like growth factors: resource allocation to fetal growth. *Journal of*
594 *Physiology*. 2017;595(15):5057-93.
- 595 39. Mifsud W, and Sebire NJ. Placental pathology in early-onset and late-onset fetal
596 growth restriction. *Fetal Diagn Ther*. 2014;36(2):117-28.
- 597 40. Brosens I, Pijnenborg R, Vercruyse L, and Romero R. The "Great Obstetrical
598 Syndromes" are associated with disorders of deep placentation. *Am J Obstet Gynecol*.
599 2011;204(3):193-201.
- 600 41. Burton GJ, and Jauniaux E. Pathophysiology of placental-derived fetal growth
601 restriction. *Am J Obstet Gynecol*. 2018;218(2S):S745-S61.
- 602 42. Kovo M, Schreiber L, Ben-Haroush A, Wand S, Golan A, and Bar J. Placental
603 vascular lesion differences in pregnancy-induced hypertension and normotensive fetal
604 growth restriction. *Am J Obstet Gynecol*. 2010;202(6):561 e1-5.
- 605 43. Colson A, Sonveaux P, Debieve F, and Sferruzzi-Perri AN. Adaptations of the human
606 placenta to hypoxia: opportunities for interventions in fetal growth restriction. *Hum*
607 *Reprod Update*. 2020.
- 608 44. Cindrova-Davies T, and Sferruzzi-Perri AN. Human placental development and
609 function. *Seminars in Cell and Developmental Biology*. 2022;In press.
- 610 45. David AL, Torondel B, Zachary I, Wigley V, Abi-Nader K, Mehta V, et al. Local
611 delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and
612 uterine blood flow in the pregnant sheep. *Gene Ther*. 2008;15(19):1344-50.

- 613 46. Sferruzzi-Perri AN. Regulating needs: Exploring the role of insulin-like growth
614 factor-2 signalling in materno-fetal resource allocation. *Placenta*. 2018;Suppl 1:S16-
615 S22.
- 616 47. Guo L, Choufani S, Ferreira J, Smith A, Chitayat D, Shuman C, et al. Altered gene
617 expression and methylation of the human chromosome 11 imprinted region in small
618 for gestational age (SGA) placentae. *Dev Biol*. 2008;320(1):79-91.
- 619 48. Yamaguchi Y, Tayama C, Tomikawa J, Akaishi R, Kamura H, Matsuoka K, et al.
620 Placenta-specific epimutation at H19-DMR among common pregnancy
621 complications: its frequency and effect on the expression patterns of H19 and IGF2.
622 *Clin Epigenetics*. 2019;11(1):113.
- 623 49. Antonazzo P, Alvino G, Cozzi V, Grati FR, Tabano S, Sirchia S, et al. Placental IGF2
624 Expression in Normal and Intrauterine Growth Restricted (IUGR) Pregnancies.
625 *Placenta*. 2008;29(1):99-101.
- 626 50. Janzen C, Lei MY, Cho J, Sullivan P, Shin BC, and Devaskar SU. Placental glucose
627 transporter 3 (GLUT3) is up-regulated in human pregnancies complicated by late-
628 onset intrauterine growth restriction. *Placenta*. 2013;34(11):1072-8.
- 629 51. Desforges M, Greenwood SL, Glazier JD, Westwood M, and Sibley CP. The
630 contribution of SNAT1 to system A amino acid transporter activity in human
631 placental trophoblast. *Biochem Biophys Res Commun*. 2010;398(1):130-4.
- 632 52. Shibata E, Hubel CA, Powers RW, von Versen-Hoeynck F, Gammill H, Rajakumar
633 A, et al. Placental System A Amino Acid Transport is Reduced in Pregnancies With
634 Small For Gestational Age (SGA) Infants but Not in Preeclampsia with SGA Infants.
635 *Placenta*. 2008;29(10):879-82.

- 636 53. Lash G, MacPherson A, Liu D, Smith D, Charnock-Jones S, and Baker P. Abnormal
637 fetal growth is not associated with altered chorionic villous expression of vascular
638 endothelial growth factor mRNA. *Mol Hum Reprod.* 2001;7(11):1093-8.
- 639 54. Lyall F, Young A, Boswell F, Kingdom JC, and Greer IA. Placental expression of
640 vascular endothelial growth factor in placentae from pregnancies complicated by pre-
641 eclampsia and intrauterine growth restriction does not support placental hypoxia at
642 delivery. *Placenta.* 1997;18(4):269-76.
- 643 55. Andraweera PH, Dekker GA, and Roberts CT. The vascular endothelial growth factor
644 family in adverse pregnancy outcomes. *Hum Reprod Update.* 2012;18(4):436-57.
- 645 56. Krishnan T, and David AL. Placenta-directed gene therapy for fetal growth
646 restriction. *Semin Fetal Neonatal Med.* 2017;22(6):415-22.
- 647 57. Ducat A, Vargas A, Doridot L, Bagattin A, Lerner J, Vilotte JL, et al. Low-dose
648 aspirin protective effects are correlated with deregulation of HNF factor expression in
649 the preeclamptic placentas from mice and humans. *Cell Death Discov.* 2019;5:94.
- 650 58. Rout M, and Lulu SS. Molecular and disease association of gestational diabetes
651 mellitus affected mother and placental datasets reveal a strong link between insulin
652 growth factor (IGF) genes in amino acid transport pathway: A network biology
653 approach. *J Cell Biochem.* 2018.
- 654 59. Brenner WE, Edelman DA, and Hendricks CH. A standard of fetal growth for the
655 United States of America. *Am J Obstet Gynecol.* 1976;126(5):555-64.
- 656 60. Mayhew TM. Stereology and the placenta: where's the point? -- a review. *Placenta.*
657 2006;27 Suppl A:S17-25.
- 658
- 659

660 **Table 1: Patient characteristics.**

Characteristics	Control (N=9)	FGR (N=7)	P-value
Maternal age	34.44 ± 1.84	32.00 ± 1.16	0.339
Maternal ethnicity	8 white, 1 non-white	2 white, 5 non-white	0.035
Booking BMI (kg/m ²)	24.67 ± 1.51	24.47 ± 2.75	0.946
Mode of delivery	4 vaginal deliveries, 5 caesarean sections	2 vaginal deliveries, 5 caesarean sections,	0.620
Gestational age at delivery (weeks)	39.14 (39.07 – 39.79)	38.29 (37.29 – 39.00)	0.006
Infant sex	4F, 5M	2F, 5M	0.633
Infant birthweight (kg)	3.53 ± 0.13	2.33 ± 0.18	< 0.001
Placental weight (g)	478.9 ± 16.6	340.7 ± 31.0	0.001

661 Data are presented as mean ± SEM and were analysed by Student's t test or Mann-Whitney U
662 test. Categorical data were analysed by 2 X 2 contingency table with Fisher's Exact Test. BMI,
663 body mass index; F, female; M, male.

664

665 **Table 2: Morphological differences in the placenta by pathology**

	Control (N=9)	FGR (N=7)	P-value ([^]FDR)
Volume density (cm³/g)			
Intervillous space	0.37±0.01	0.36±0.02	0.447
Stem villi	0.06±0.01	0.06±0.01	0.895
Intermediate villi	0.12±0.01	0.08±0.01	0.008*
Terminal villi	0.42±0.02	0.4±0.03	0.474
Syncytial knots	0.02±0.00	0.01±0.00	0.002*
Fibrosis	0.01±0.01	0.1±0.02	0.001*
Trophoblast	0.32±0.01	0.34±0.03	0.583
Stromal	0.55±0.02	0.45±0.05	0.058
Capillary	0.13±0.01	0.21±0.03	0.016*
Volume (cm³)			
Intervillous space	179.73±9.45	119.44±10.77	0.001*
Stem villi	27.83±3.2	20.17±4.25	0.163
Intermediate villi	55.4±4.41	25.48±2.43	<0.001*
Terminal villi	200.73±10.54	135.3±16.23	0.003*
Syncytial knots	8.39±0.78	2.44±0.71	<0.001*
Fibrosis	5.88±3.24	37.02±7.43	0.001*
Trophoblast	153.5±6.83	114.7±13.69	0.017*
Stromal	263.09±15.46	153.23±21.66	0.001*
Capillary	62.3±5.04	72.78±13.76	0.445
Barrier thickness (µm)			

Arithmetic mean	2.83±0.08	2.85±0.18	0.912
Harmonic mean	2.14±0.07	2.24±0.14	0.500
Thickness uniformity index (a measure of thickness variability)	1.32±0.01	1.48±0.08	0.044
Surface density (cm²/cm³)			
Villi	610.45±23.85	630.28±44.68	0.683
Fetal capillary	298.26±19.81	401.92±48.29	0.048
Surface area (m²)			
Villi	11.68±2.88	10.59±1.55	0.009*
Fetal capillary	6.27±1.7	6.89±1.23	0.576
Theoretical diffusion capacity (cm²/min/kPa)	95.29±4.86	70.26±11.5	0.047
Specific diffusion capacity (cm²/min/kPa/g)	27.2±1.49	29.47±3.99	0.567

666 Data presented as mean ± SEM and analysed by t test with FDR (false discovery correction)

667 correction at 5%. * Denotes significant findings that passed the 5% FDR.

668

669 **Table 3: Predictive modelling results using different machine learning methods.**

Peripheral & Central									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.899	0.913	0.927	0.705	0.733	0.719	0.875	0.92	0.948
AUC for all patients	0.611	0.861	0.917	0.639	0.528	0.528	0.694	0.861	0.917
Peripheral									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.903	0.938	0.924	0.681	0.694	0.681	0.819	0.938	0.979
AUC for all patients	0.861	0.917	0.861	0.556	0.556	0.556	0.778	0.917	0.917
Central									
	Stereology			qPCR			Stereology & qPCR		
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
AUC for all samples	0.889	0.903	0.903	0.722	0.694	0.722	0.826	0.889	0.889

AUC for all patients	0.778	0.861	0.861	0.611	0.611	0.611	0.722	0.861	0.806
----------------------	-------	-------	-------	-------	-------	-------	-------	-------	-------

670 **Results for each combination of “placenta part + type of measurement + ML model”** The

671 best version of the model is *nnet* model (highlighted in bold) on peripheral parts of placenta

672 using stereological and qPCR data together. In this case, “AUC for all patients” = 0.917

673 (corresponding to an error for just one patient-case in a sample of 15 patients: 9 controls and 6

674 FGR), and “AUC for all samples” = 0.979 (corresponding to an error for only one

675 measurement, a FGR in a set of 15*4 samples: 9*4 control samples and 6*4 FGR samples). A

676 complete table of errors is given in Supplementary Table 3.

677


678

679 **Table 4 Probes used for real-time PCR**


Analysed genes	Gene symbol	Probe ID	Fluorophore
Housekeeping genes	<i>18S rRNA</i>	Hs99999901_s1	VIC
	<i>B2M</i>	Hs00187842_m1	VIC
	<i>GAPDH</i>	Hs02786624_g1	VIC
	<i>GUSB</i>	Hs00939627_m1	VIC
	<i>YWHAZ</i>	Hs01122445_g1	VIC
Genes of interest	<i>HNF1A</i>	Hs00167041_m1	VIC
	<i>IGF2</i>	Hs04188276_m1	FAM
	<i>SLC2A1</i>	Hs00892681_m1	FAM
	<i>SLC2A3</i>	Hs00359840_m1	FAM
	<i>SLC38A1</i>	Hs01562175_m1	FAM
	<i>SLC38A2</i>	Hs01089954_m1	VIC
	<i>SLC38A4</i>	Hs00394339_m1	FAM
	<i>VEGFA</i>	Hs00900055_m1	FAM

680

681




683 **Figure 1: Relative mRNA expression of selected growth factors and nutrient transporters**
684 **in control and FGR placentas.** Expression of growth factors (*IGF2*, *VEGFA*), and
685 transporters (*SLC2A1*, *SLC2A3*, *SLC38A1*, *SLC38A2* and the transcription factor *HNF1A*), were
686 evaluated by qPCR. A total of 3 outliers were excluded; 1 control peripheral value for *VEGFA*,
687 and 1 control central value and 1 control peripheral value for *HNF1A*. Data are presented with
688 individual data points with mean \pm SEM and analysed with two-way ANOVA, followed by
689 Sidak's post hoc test for multiple comparisons. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
690 **** $p < 0.0001$.
691



692

693 **Figure 2. Correlations between stereological parameters and the relative expression of**
 694 **functional genes in the placenta.** Pearson's r coefficient was plotted and used to indicate
 695 strength of relationship between data (0: low, 1: high) and direction of correlation (+ sign:
 696 direct correlation and – sign: inverse correlation). Analysis was performed on each sampling
 697 site and experimental group (control and FGR) separately. Sample size was 36 for control and
 698 24 for FGR. *: p < 0.05, correlation is statistically significant.

699




700

701 **Figure 3: Distributions of AUCs, i.e., the performance results of different types of models**

702 **on different types of data obtained on different parts of the placenta for all patients and**

703 **for all their measurements separately.**

704



705

706 **Figure 4. Diagram showing sampling of placenta (A) and main parameters measured in**

707 **histological sections of placenta (B-D).** (A) Dotted lines indicate where the placenta should

708 be cut with a sterile histology knife. Red boxes with single letters indicate inner sections.

709 Yellow boxes with double letters indicate outer sections. Green rectangles represent samples

710 taken for RNA sampling. The central blue circle represents the umbilical cord (cut). (B-D)

711 Representative histological sections of term human placenta. Stereological analysis was

712 performed by identifying the intervillous space (IVS), stem villi (SV), intermediate villi

713 (INTV), terminal villi (TV), fibrosis (FIB), syncytial knots (*); and under higher magnification

714 of terminal villi, the trophoblast cell layer (#), fetal capillaries (+) and stromal cells (^). The

715 scale bar denotes 50 μ m.

716